These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 16609811)

  • 1. Mitoxantrone versus cyclophosphamide in secondary-progressive multiple sclerosis: a comparative study.
    Perini P; Calabrese M; Tiberio M; Ranzato F; Battistin L; Gallo P
    J Neurol; 2006 Aug; 253(8):1034-40. PubMed ID: 16609811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous mitoxantrone and cyclophosphamide as second-line therapy in multiple sclerosis: an open-label comparative study of efficacy and safety.
    Zipoli V; Portaccio E; Hakiki B; Siracusa G; Sorbi S; Amato MP
    J Neurol Sci; 2008 Mar; 266(1-2):25-30. PubMed ID: 17870094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitoxantrone for multiple sclerosis.
    Martinelli Boneschi F; Vacchi L; Rovaris M; Capra R; Comi G
    Cochrane Database Syst Rev; 2013 May; (5):CD002127. PubMed ID: 23728638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A cost-utility analysis of mitoxantrone hydrochloride and interferon beta-1b in the treatment of patients with secondary progressive or progressive relapsing multiple sclerosis.
    Touchette DR; Durgin TL; Wanke LA; Goodkin DE
    Clin Ther; 2003 Feb; 25(2):611-34. PubMed ID: 12749517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ
    Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of the benefits of mitoxantrone and other recent therapeutic approaches in multiple sclerosis.
    Gonsette RE
    Expert Opin Pharmacother; 2004 Apr; 5(4):747-65. PubMed ID: 15102561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mitoxantrone therapy in rapidly worsening multiple sclerosis.
    Benesova Y; Stourac P; Beranek M; Kadanka Z
    Bratisl Lek Listy; 2005; 106(3):141-3. PubMed ID: 16026151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of progressive multiple sclerosis with monthly pulsed cyclophosphamide-methylprednisolone: predictive factors of treatment response].
    Delmont E; Chanalet S; Bourg V; Soriani MH; Chatel M; Lebrun C
    Rev Neurol (Paris); 2004 Jul; 160(6-7):659-65. PubMed ID: 15247854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Aggressive multiple sclerosis. Definition and specific therapeutic indication].
    Edan G
    Presse Med; 2004 Feb; 33(3):187-91; discussion 192. PubMed ID: 15029034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The argument against the use of cyclophosphamide and mitoxantrone in the treatment of multiple sclerosis.
    Jeffery DR
    J Neurol Sci; 2004 Aug; 223(1):41-6. PubMed ID: 15261559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of mitoxantrone use in primary and secondary progressive multiple sclerosis - study site experience based on the therapy of 104 patients.
    Lasek-Bal A; Bartoszek K; Steposz A; Puz P; Bal W; Kazibutowska Z
    Int J Neurosci; 2017 Oct; 127(10):859-863. PubMed ID: 27919195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Re-examining the effects of high-dose intravenous methylprednisolone for secondary progressive multiple sclerosis.
    Jalipa FGU; Espiritu AI; Pasco PMD
    Neurodegener Dis Manag; 2021 Apr; 11(2):177-185. PubMed ID: 33703936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of progressive forms of multiple sclerosis by cyclophosphamide: a cohort study of 490 patients.
    Zephir H; de Seze J; Duhamel A; Debouverie M; Hautecoeur P; Lebrun C; Malikova I; Pelletier J; Sénéchal O; Vermersch P
    J Neurol Sci; 2004 Mar; 218(1-2):73-7. PubMed ID: 14759636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mitoxantrone as a potential therapy for primary progressive multiple sclerosis.
    Stüve O; Kita M; Pelletier D; Fox RJ; Stone J; Goodkin DE; Zamvil SS
    Mult Scler; 2004 Jun; 10 Suppl 1():S58-61. PubMed ID: 15218811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Escalating immunotherapy with mitoxantrone in patients with very active relapsing-remitting or progressive multiple sclerosis.
    Cursiefen S; Flachenecker P; Toyka KV; Rieckmann P
    Eur Neurol; 2000; 43(3):186-7. PubMed ID: 10765063
    [No Abstract]   [Full Text] [Related]  

  • 17. Double-Blind Controlled Randomized Trial of Cyclophosphamide versus Methylprednisolone in Secondary Progressive Multiple Sclerosis.
    Brochet B; Deloire MS; Perez P; Loock T; Baschet L; Debouverie M; Pittion S; Ouallet JC; Clavelou P; de Sèze J; Collongues N; Vermersch P; Zéphir H; Castelnovo G; Labauge P; Lebrun C; Cohen M; Ruet A;
    PLoS One; 2017; 12(1):e0168834. PubMed ID: 28045953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical follow-up of 304 patients with multiple sclerosis three years after mitoxantrone treatment.
    Debouverie M; Taillandier L; Pittion-Vouyovitch S; Louis S; Vespignani H
    Mult Scler; 2007 Jun; 13(5):626-31. PubMed ID: 17548442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of mitoxantrone in pediatric patients with aggressive multiple sclerosis.
    Etemadifar M; Afzali P; Abtahi SH; Ramagopalan SV; Nourian SM; Murray RT; Fereidan-Esfahani M
    Eur J Paediatr Neurol; 2014 Mar; 18(2):119-25. PubMed ID: 24139067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review of mitoxantrone in the treatment of multiple sclerosis.
    Jeffery DR; Herndon R
    Neurology; 2004 Dec; 63(12 Suppl 6):S19-24. PubMed ID: 15623665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.